{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T23:28:32Z","timestamp":1720481312692},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1016\/j.bone.2006.01.152","type":"journal-article","created":{"date-parts":[[2006,3,8]],"date-time":"2006-03-08T12:31:19Z","timestamp":1141821079000},"page":"S13-S17","source":"Crossref","is-referenced-by-count":4,"special_numbering":"S1","title":["Beyond daily dosing: Clinical experience"],"prefix":"10.1016","volume":"38","author":[{"given":"C.","family":"Cooper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2006.01.152_bib1","unstructured":"International Osteoporosis Foundation. Osteoporosis in the European community: action plan. International Osteoporosis Foundation 2003. Available from: http:\/\/www.osteofound.org\/advocacy_policy\/eu_policy_project\/pdf\/action_plan_03_e.pdf. Accessed 8 August 2005."},{"issue":"Suppl. 5","key":"10.1016\/j.bone.2006.01.152_bib2","doi-asserted-by":"crossref","first-page":"505S","DOI":"10.1016\/8756-3282(95)00258-4","article-title":"The worldwide problem of osteoporosis: insights afforded by epidemiology","volume":"17","author":"Riggs","year":"1995","journal-title":"Bone"},{"key":"10.1016\/j.bone.2006.01.152_bib3","unstructured":"International Osteoporosis Foundation. International Osteoporosis Foundation: Annual Report 2004. International Osteoporosis Foundation 2004. Available from: http:\/\/www.osteofound.org\/iof\/pdf\/report_2004.pdf. Accessed 17 May 2005."},{"key":"10.1016\/j.bone.2006.01.152_bib4","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1001\/archinte.151.10.2026","article-title":"A model of lifetime osteoporosis impact","volume":"151","author":"Chrischilles","year":"1991","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.bone.2006.01.152_bib5","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1532-5415.1995.tb05557.x","article-title":"Late physical and functional effects of osteoporotic fracture in women: the Rancho Bernardo Study","volume":"43","author":"Greendale","year":"1995","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.bone.2006.01.152_bib6","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/oxfordjournals.aje.a116756","article-title":"Population-based study of survival after osteoporotic fractures","volume":"137","author":"Cooper","year":"1993","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.bone.2006.01.152_bib7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0889-857X(05)70197-6","article-title":"The nonskeletal consequences of osteoporotic fractures. Psychologic and social outcomes","volume":"27","author":"Gold","year":"2001","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"10.1016\/j.bone.2006.01.152_bib8","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.01.152_bib9","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00198-004-1602-9","article-title":"Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study","volume":"15","author":"Delmas","year":"2004","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2006.01.152_bib10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2006.01.152_bib11","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2006.01.152_bib12","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2006.01.152_bib13","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2006.01.152_bib14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2006.01.152_bib15","unstructured":"Alendronate prescribing information. December 2004 (www.fosamax.com)."},{"key":"10.1016\/j.bone.2006.01.152_bib16","unstructured":"Risedronate prescribing information. March 2003 (www.actonel.com)."},{"key":"10.1016\/j.bone.2006.01.152_bib17","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/jbmr.5650060915","article-title":"BM 21.0955, a potent new bisphosphonate to inhibit bone resorption","volume":"6","author":"M\u00fchlbauer","year":"1991","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.01.152_bib18","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00198-004-1612-7","article-title":"Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing","volume":"15","author":"Bauss","year":"2004","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2006.01.152_bib19","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S8756-3282(96)00229-3","article-title":"The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of PMO: a 1-year, randomized, double-blind, placebo-controlled dose-finding study","volume":"19","author":"Ravn","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.bone.2006.01.152_bib20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0149-2918(03)90005-1","article-title":"Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies","volume":"25","author":"Schimmer","year":"2003","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bone.2006.01.152_bib21","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1359\/jbmr.2001.16.10.1871","article-title":"Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis","volume":"16","author":"Riis","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.01.152_bib22","series-title":"Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis","author":"United States Food and Drug Administration","year":"1994"},{"issue":"Suppl 1","key":"10.1016\/j.bone.2006.01.152_bib23","first-page":"S206","article-title":"Efficacy of oral ibandronate in postmenopausal osteoporosis: incidence of vertebral fractures by subgroup","volume":"17","author":"Ettinger","year":"2002","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.01.152_bib24","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group","volume":"333","author":"Liberman","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2006.01.152_bib25","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2006.01.152_bib26","unstructured":"F. Hoffmann-La Roche Ltd\/GlaxoSmithKline data on file."},{"key":"10.1016\/j.bone.2006.01.152_bib27","first-page":"1377","article-title":"Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis","volume":"4","author":"Ettinger","year":"1998","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.bone.2006.01.152_bib28","doi-asserted-by":"crossref","first-page":"488","DOI":"10.18553\/jmcp.1998.4.5.488","article-title":"Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation","volume":"4","author":"Ettinger","year":"1998","journal-title":"J. Manag. Care Pharm."},{"key":"10.1016\/j.bone.2006.01.152_bib29","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1136\/bmj.315.7117.1235a","article-title":"Incidence of gastrointestinal side effects due to alendronate is high in clinical practice","volume":"315","author":"Kelly","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.bone.2006.01.152_bib30","first-page":"51","article-title":"The clinical tolerability profile of alendronate","volume":"101","author":"Watts","year":"1999","journal-title":"Int. J. Clin. Pract., Suppl."},{"key":"10.1016\/j.bone.2006.01.152_bib31","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1001\/archinte.160.4.517","article-title":"Upper gastrointestinal safety profile of alendronate. The Fracture Intervention Trial","volume":"160","author":"Bauer","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.bone.2006.01.152_bib32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1385\/JCD:6:1:45","article-title":"Bone density changes with once weekly risedronate in postmenopausal women","volume":"6","author":"Delaney","year":"2003","journal-title":"J. Clin. Densitom."},{"key":"10.1016\/j.bone.2006.01.152_bib33","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/BF01622190","article-title":"Pamidronate: an unrecognised problem in gastrointestinal tolerability","volume":"4","author":"Lufkin","year":"1994","journal-title":"Osteoporos. Int."},{"issue":"Suppl. 9","key":"10.1016\/j.bone.2006.01.152_bib34","first-page":"S84","article-title":"Favorable upper gastrointestinal safety profile of ibandronate in patients with a history of gastrointestinal disorders or receiving concomitant NSAIDs","volume":"48","author":"Rosen","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2006.01.152_bib35","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","article-title":"Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study","volume":"20","author":"Miller","year":"2005","journal-title":"J. Bone Miner. Res."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328206002250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328206002250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T17:41:59Z","timestamp":1627148519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328206002250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["S8756328206002250"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2006.01.152","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}